Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results
Provided By GlobeNewswire
Last update: Aug 14, 2025
FDA confirms requirement for confirmatory study of roluperidone for the treatment of negative symptoms in schizophrenia
Evaluation of strategic alternatives
Read more at globenewswire.comNASDAQ:NERV (12/2/2025, 12:32:19 PM)
3.45
-0.35 (-9.21%)
Find more stocks in the Stock Screener
